eli lilly trials retatrutide A Study of (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Lilly's triple agonist achieves 16.8%

"Once-Weekly Semaglutide in Adults with Overweight or Obesity"

Safety and Side Effects Like all therapies, GLP-1 medications can have side effects most commonly digestive symptoms such as nausea, vomiting, or constipation as the body adjusts

Studies suggest that BPC-157 positively influences angiogenesis, the process of blood vessel creation which is closely related to healing of damaged tissue

doi: 10.1056/NEJMoa2008250 28 TeitsmaXMMarijnissenAKBijlsmaJWLafeberFPJacobsJW

Many patients: Dont need to lose 25-30% of their body weight Dont want to take an injection or simply prefer an oral tablet Dont live in an area where cold-chain injectables are easy to manage May be able to maintain their weight after an injection-based therapy with orals There are oral GLP1s+ showing great potential in current studies: Lillys Orforglipron: ~15% weight loss (similar to Wegovy), not impacted by meals, etc

Hristakeva, S., Liaukonyte, J., and Feler, L